Veterinary Sciences· 2026Q1
Intra-Articular Autologous Conditioned Serum Alone or Combined with Oral Cannabidiol in Dogs Undergoing Tibial Plateau Leveling Osteotomy: An Exploratory Randomized Controlled Trial
- 0citations
- Q1SCImago
- 2026year
Short summary
Combining intra-articular autologous conditioned serum (ACS) with oral cannabidiol (CBD) reduced C-reactive protein (CRP) levels on days 3 and 5 post-surgery in dogs undergoing tibial plateau leveling osteotomy, compared to placebo.
AI-generated from the title and abstract; the full text is not read.
Key points
- Twenty-seven dogs undergoing tibial plateau leveling osteotomy were randomized into placebo, ACS, or ACS + CBD groups (n=9/group).
- C-reactive protein (CRP) levels peaked on day 1 post-surgery across all groups.
- The ACS + CBD group exhibited significantly lower CRP on post-operative days 3 (adjusted p=0.007) and 5 (adjusted p=0.001) compared to placebo.
- No consistent treatment-group differences were observed in clinical assessments (lameness, mobility, pain, weight-bearing) or radiographic outcomes.
- One dog in the ACS group developed a surgical site infection; higher alkaline phosphatase was noted in the ACS + CBD group on day 28.
AI-generated from the title and abstract; the full text is not read.
Abstract
Autologous conditioned serum (ACS) contains anti-inflammatory mediators, whereas cannabidiol (CBD) may have analgesic and immunomodulatory effects. This exploratory randomized trial evaluated intra-articular ACS, alone or combined with oral CBD, after tibial plateau leveling osteotomy in dogs. Twenty-seven dogs were randomized to placebo, ACS, or ACS + CBD (n = 9/group). Outcomes included C-reactive protein (CRP), peak vertical force, orthopedic assessment scores (lameness, joint mobility, pain on palpation, weight-bearing, and overall clinical condition), Canine Brief Pain Inventory, radiographic outcomes, and safety. CRP peaked on Day 1. In the linear mixed model using a heterogeneous first-order autoregressive covariance structure, treatment-group (p = 0.001) and visit (p < 0.001) effects were significant, whereas the treatment-group × visit interaction did not reach significance (p = 0.053). Exploratory comparisons showed lower CRP in ACS + CBD than placebo on Days 3 (adjusted p = 0.007) and 5 (adjusted p = 0.001), with model-dependent sensitivity findings. No consistent treatment-group differences were identified in clinical or structural outcomes. One ACS-treated dog developed a surgical site infection, and alkaline phosphatase activity was higher in ACS + CBD on Day 28. The CRP findings remain hypothesis-generating, with uncertain clinical relevance.
The authors' abstract, as published at the source. Veterinary Sciences, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Small AnimalsVeterinary